Cybin (CYBN.NE) announced that they have received conditional approval to join the New York Stock Exchange (NYSE), specifically, the NYSE American LLC stock exchange. Cybin has reserved the ticker…
CYBN
Cybin (CYBN.NE) announced that they will be using Alcohol Use Disorder (AUD) as the initial target indication for their proprietary psychedelic molecule, CYB003. “AUD is a chronic relapsing brain…
Cybin (CYBN.NE) announced they are forming a Clinical Advisory Board, which will be chaired by Alex Belser, Cybin’s Chief Clinical Officer. The board will consist of Belser (PhD), Maurizio…
Cybin (CYBN.NE) announced its plans to advance the pre-clinical work for two of its molecules: its orally dissolving tablet (ODT) formulation CYB003 and its inhaled formulation CYB004. These…
Cybin (CYBN.NE) announced changes to the senior management team effective immediately, with some positions being filled by new members of the team and other current management moving to new…
Canada: not a big push for rec Canada is a country typically at the forefront of forward-thinking movements in health and science. With the recent legalization of cannabis…